PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Janssen-Cilag Ltd
JA

Janssen-Cilag Ltd

Buckinghamshire
Large

Janssen-Cilag Ltd is the UK pharmaceutical subsidiary of Johnson & Johnson, researching, developing, and commercialising innovative medicines across oncology, immunology, neuroscience, and cardiovascular disease. The company is committed to improving patient outcomes through breakthrough pharmaceutical innovations and scientific partnerships.

janssen.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£1.0bn
Live
60
Buyers
9
12m
£589.1m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities6
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts60 / 95
  • Top buyers9
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Janssen-Cilag LtdUpdated 06 Jul 2026

At a glance · for buyers and watchdogs

Janssen-Cilag Ltd has won £1.0bn across 9 public-sector buyers, with 60 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 99% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
60 of 95Live contracts
99%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value · 2/5

Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.

◐ From supplier website
JobsNo commitment stated✓
SkillsNo commitment stated✓
Environment1 commitment✓
Tackling inequalityNo commitment stated✓
Community1 commitment✓
Environment · 1
  • WebsiteCarbon net zero targetCarbon neutral by 2045
Community · 1
  • WebsiteCommunity initiativesPatient access programs and healthcare research partnerships

Extracted automatically from janssen.com on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 6
Oncology Medicines
Immunology Medicines
Neuroscience Medicines
Cardiovascular Medicines
Pharmaceutical Research
Clinical Development
Frameworks & DPS · 6 from notices
  • NHS England Framework Agreement: South of England (Tranche B)NHS England · £15.7m
  • NHS Framework Agreement, Branded Medicines for London and South of EnglandNHS England · £13.3m
  • NHS England Framework Agreement - London - Tranche ANHS England · £10.6m
  • NHS Framework Agreement for Proprietary Pharmaceuticals - South of England (Tranche A)NHS England · £10.5m
  • NHS England - Midlands and East Branded Medicines - Tranche BNHS England · £9.2m
  • NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder OpportunityNHS England · £8.4m

Extracted automatically from janssen.com on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships · 2

Credentials listed on the supplier’s website. Not yet checked against issuer registers.

◐ From supplier website
Core credentials · 2/6
Cyber EssentialsNot evidenced✓
Cyber Essentials PlusNot evidenced✓
ISO 27001 — Information securityNot evidenced✓
ISO 9001 — QualityListed on site✓
ISO 14001 — EnvironmentalListed on site✓
ISO 45001 — Health & safetyNot evidenced✓

Extracted automatically from janssen.com on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 60 live · 35 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Branded Interim - 1 June 2026
NHS England—01 Jun 2026£529.1m1.9 yrspending
NHS National Framework for Golimumab Injection
NHS England—01 Nov 2025£60.0m12 mopending
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
NHS England3360000001 Sept 2025£47.0m2 yrsLive
NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National
NHS England3360000001 Sept 2025£9.4m2 yrsLive
NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024
NHS England3360000001 Nov 2024£48.2m2 yrsLive
NHS Branded Medicines Tranche Framework for London and South of England
NHS England3360000001 Sept 2024£13.1m2 yrsLive
NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024
NHS England3360000001 May 2024£11.2m4 yrsLive
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)
NHS England3360000001 Jun 2024£0.023 yrsLive
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
NHS England3360000001 Mar 2024£17.6m2.5 yrsLive
NHS South of England Branded Medicines - Tranche A - September 2023
NHS England3360000001 Sept 2023£7.6m2 yrsClosed
Total live value £146.5m · mean award £11.0m1–10 of 95

Top buyers · 9 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
65 contracts
99%
since 2017
2
NHSE&I
1 contract
1%
since 2022
3
eTenderwales
1 contract
0%
4
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
17 contracts
0%
5
Procurement and Logistics Service
3 contracts
0%
6
Procurement and Logistics Service, Business Services Organisation
1 contract
0%
7
The NHS Commissioning Board (operating under the name of NHS England)
5 contracts
0%
8
Northern Health and Social Care Trust NHSCT
1 contract
0%
9
BELFAST HEALTH AND SOCIAL CARE TRUST
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire65 contracts
100%
Wales1 contract
0%
Scotland17 contracts
0%
Northern Ireland6 contracts
0%
North West5 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Janssen-Cilag Ltd highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
JA
Janssen-Cilag Ltd
No£589.1m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m17
AB
AbbVie Ltd
Yes£95.2m11
TA
Thornton and Ross Ltd
Yes£72.5m9
AC
ACCORD-UK LTD
Yes£71.2m18
PF
Pfizer Ltd
Yes£69.8m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 29 Dec 2024
Confirmation statement
Up to date
Next due 24 Jan 2027
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
01027904
Status
Active
Type
Private limited
Incorporated
19 Oct 1971
Reg. office
50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG
SIC codes
21200
Last accounts
29 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • GOMEZ LORA, Maria Alexandra — director
    Appointed 18 Mar 2026
  • DRAPER, Charlotte — director
    Appointed 30 Sept 2024
  • FLEMING, John David, Dr — director
    Appointed 15 Mar 2024
  • BEKKER, Rozlyn — director
    Appointed 29 Mar 2023
  • ILBERT, Robin John — director
    Appointed 01 Jan 2020
  • Johnson & Johnson — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
JANSSEN-CILAG LIMITED
01027904 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.